Here, we assessed the efficacy of EGFR mAbs in simultaneous and sequential combinations with oxaliplatin in a panel of colorectal cancer cell lines with different genetic backgrounds (wild-type or mutant for KRAS or BRAF). The gene discussed is KRAS; the disease is colorectal cancer.